Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn:
”As with other advanced therapies, access to gene therapy in hemoglobinopatías will face, once funded, equity risks arising from its high cost and the authorization of only certain centers for its administration.
For example, patients could be induced to participate in a particular clinical trial rather than referred to the referral center for therapy, or “own” patients could be prioritized over referrals at the referral center.
These risks may be greater in haemoglobinopathies compared to other diseases, as they are rare diseases in which management expertise is limited to a few centres and because they preferentially affect, especially sickle cell disease, marginalised groups.
In addition, patients will have to “compete” for hospital beds with patients with haematological cancer, for whom there is already a lack of beds, with a greater vital urgency in terms of treatment and greater awareness of the disease among decision-making health teams.
In this context, the efforts of the pharmaceutical industry, patient associations, and the scientific community should not be satisfied with funding, but in parallel and in advance the equidad should be addressed.
The creation of a national committee of experts for the review of proposed patients, or the development of a national “prioritization protocol” like that of a North American institution published a few days ago are examples of feasible strategies.”
Read the full article in Blood Advances.
Article: An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent β-thalassemia
Authors: Amar H. Kelkar, Maureen O. Achebe, Andrew Hantel
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals